|Bid||9.81 x 42300|
|Ask||10.00 x 900|
|Day's Range||10.16 - 11.12|
|52 Week Range||5.27 - 18.50|
|Beta (3Y Monthly)||0.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2019 - Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.04|
Endo International PLC (NASDAQ: ENDP) stock dropped 8.53 percent Friday after “60 Minutes” announced it will be featuring attorney general and Ohio governor-elect Mike DeWine on Sunday’s episode. What Happened? “60 Minutes,” which has been known to move markets with its exposes, announced that Sunday’s episode of the show will be focused on “shocking” data DeWine has uncovered that's related to opioid distribution. Endo is one of the companies included in lawsuits in Ohio, Missouri and Mississippi related to its role in the opioid epidemic.
BOSTON, MA / ACCESSWIRE / December 14, 2018 / Block & Leviton LLP ( www.blockesq.com ), a securities litigation firm representing investors nationwide, is investigating whether Endo International PLC ("Endo" ...
Endo International shares fell 8 percent after news of a report by CBS' "60 Minutes" about data collected by opioid distributors on amounts and destinations of painkillers. The data tracking amounts and destinations of painkillers were part of a confidential reporting system distributors shared with the Drug Enforcement Agency, the report, which is slated to air Sunday, says.
Billionaire hedge fund managers such as Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the big players […]
The treatment is a reformulated version of the company's commonly abused painkiller Roxicodone, intended to make the drug less desirable and more difficult to be abused by snorting or injecting. Mallinckrodt's shares fell 4.4 percent to $20.02 in premarket trading on Wednesday. The decision comes after an advisory panel to the FDA voted 10-7 in favor of the drug, saying it should be labeled as abuse deterrent only by the nasal route.
In December 2018, of the total 16 analysts covering Endo International (ENDP), five analysts have given Endo stock a “buy” or higher rating and 11 analysts have given it a “hold” rating. The mean rating for Endo International stock is 2.5 with a target price of $17.04, implying an upside potential of 47.3% over Endo International’s closing price of $11.57 on December 7, 2018.
How's Endo International Positioned in December? Endo International (ENDP) incurred net interest expenses of $131.85 million in the third quarter of 2018 as compared with $127.52 million in the year-ago period. Endo International’s net loss per share was $0.43 in the third quarter of 2017.
Endo International’s (ENDP) next two business segments are: The US Generic Pharmaceuticals segment includes solid oral extended release, solid oral immediate release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, and sprays. Revenues from this segment declined from $294.75 million in the third quarter of 2017 to $257.97 million in the third quarter of 2018. The International Pharmaceuticals segment revenues also declined from $56.43 million in the third quarter of 2017 to $30.25 million in the third quarter of 2018.
How's Endo International Positioned in December? For fiscal 2018 and 2019, Endo is expected to incur research and development expenses of $162.01 million and $165.43 million, respectively. Endo expects its US generic pharmaceuticals research and development costs to decline due to its moving its R&D activities to India.
How's Endo International Positioned in December? Endo International (ENDP) is a global specialty pharmaceutical company with a focus on generic and branded pharmaceuticals. Endo International generated total revenues of $745.47 million in the third quarter of 2018 as compared with $786.89 million in the comparable period of 2017.
NEW YORK, Dec. 04, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
DUBLIN , Nov. 28, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that members of management will participate in a fireside chat at the Bank of America Merrill Lynch Leveraged ...
DUBLIN , Nov. 26, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that members of management will participate in a fireside chat at the Piper Jaffray Global Healthcare Conference ...
On Nov. 19, Bill Miller of Miller Value Partners published notes on his third-quarter 2018 investor call. The last time I updated you on Miller, he saw a bull market without end . There are four main subjects: market observations, the government deficit, tariffs and interest rates in relationship to market price-earnings ratios.
Bausch Health’s (BHC) wholly owned subsidiary Salix Pharmaceuticals generated revenues of $460.0 million in the third quarter compared to $452.0 million in the third quarter of 2017, reflecting ~2% YoY growth. Xifaxan and Relistor primarily contributed to the revenue growth of Salix Pharmaceuticals in the third quarter. In the third quarter, Xifaxan and Relistor witnessed ~11% and 88% YoY organic revenue growth.
On November 13, Bausch Health stock closed at $26.63, which is a ~1.60% increase from its prior close of $26.21 on November 12, 2018. On November 13, Bausch Health stock closed at $26.63, a ~92% increase from its 52-week low of $13.86 on November 15, 2017. On October 3, 2018, Bausch Health hit its 52-week high of $28.45.
This mutual fund is focused on small-cap stocks, and the fund's managers like the outlook for small caps.
The best pharmaceutical stocks to buy have a commonality: Strong Composite Ratings and Relative Strength Ratings.